EP0593573A1 - Formulation pharmaceutique comprenant une beta-lactamine et de l'acide clavulanique ou un sel de celui-ci soluble dans l'eau - Google Patents
Formulation pharmaceutique comprenant une beta-lactamine et de l'acide clavulanique ou un sel de celui-ci soluble dans l'eauInfo
- Publication number
- EP0593573A1 EP0593573A1 EP92914294A EP92914294A EP0593573A1 EP 0593573 A1 EP0593573 A1 EP 0593573A1 EP 92914294 A EP92914294 A EP 92914294A EP 92914294 A EP92914294 A EP 92914294A EP 0593573 A1 EP0593573 A1 EP 0593573A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical formulation
- acid
- salt
- formulation according
- dicarboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Definitions
- This invention relates to pharmaceutical formulations, in particular to formulations containing ⁇ -lactam antibiotics and the ⁇ -lactamase inhibitor clavulanic acid or derivatives thereof, especially aqueous suspension formulations.
- compositions containing a ⁇ -lactam antibiotic and clavulanic acid or derivatives such as its salts are known.
- Clavulanic acid in aqueous suspension or solution is known to suffer to some extent from instability, and one significant determinant of stability is the pH of the aqueous medium of the suspension or solution, pH 5.8 - 6.2 being known to be the optimum.
- This invention provides novel improved pharmaceutical formulations containing clavulanic acid or derivatives thereof in which these problems have to some extent been alleviated, and further unexpected advantages have been achieved.
- the invention provides a pharmaceutical formulation comprising;
- the formulation may be an aqueous suspension or solution formulation, eg for oral administration or may alternatively be a dry powder, granular or tablet formulation provided primarily for reconstitution into an aqueous suspension or solution formulation.
- the one or more ⁇ -lactam antibiotics may be penicillins or cephalosporins, especially amox cillin and ampicillin, preferably amoxycillin in the form of its trihydrate.
- the clavulanic acid is preferably in the form of one of its salts with a pharmaceutically acceptable cation, especially potassium clavulanate.
- the weight ratio of antibiotic: clavulanic acid or clavulanate anion equivalent is in the range 12 : 1 to 1 : 1, suitably 8 : 1 to 1.5 : 1.
- concentration of antibiotic and clavulanic acid or clavulanate equivalent will vary depending upon the size of the unit dose in which it is intended to be administered.
- formulations for oral administration are administered in unit doses of around 5ml spoonfuls or as paediatric drops for small children.
- the total combined concentration of antibiotic and clavulanic acid or equivalent in such suspensions or solutions may be in the range 25 - 250 mg/ml, for example 30-125 mg/ml.
- the formulation is in the form of dry powder, granules or tablets for reconstitution the quantity of antibiotic and clavulanic acid or equivalent may be derived accordingly.
- the dicarboxylic acid salt eg. a succinic acid salt may be of a divalent cation such as calcium or other pharmaceutically acceptable cation, eg of a Group II metal, in which case a single such cation may replace both of the acidic hydrogen atoms.
- each acidic hydrogen atom may be replaced by a monovalent cation such as sodium, potassium or other pharmaceutically acceptable monovalent cation.
- Disodium succinate is preferred on account of its low cost, used in combination with succinic acid.
- the weight ratio of succinic acid : disodium succinate may be in the range 1 : 50 to 1 : 0.05 representing a molar ratio of succinic acid : succinic acid salt in the range 1 : 33 to 3 : 1.
- Suitable weight ratios of succinic acid : disodium succinate are around 1 : 30 to 1 : 15, for example 1 : 19 ⁇ 1.
- Typical weight ranges for other salts may be calculated from these ranges on the basis of the corresponding weight of succinate anion.
- the total molarity of succinic acid and succinate salt may be in the range 0.001M to 0.01M, suitably 0.001M to 0.0052 M, for example 0.005 ⁇ 0.0001 M.
- the formulation is in the form of dry powder, granules or tablets for reconstitution the quantity of succinic acid and succinate salt may be derived accordingly.
- the formulation may also optionally contain excipients which may be essentially conventional in the art.
- aqueous suspension or solution formulations may typically contain suspending agents such as Xantham gum, for example 0.25-5 mg/ml, suitably 0.5 - 2.5 mg/ml, thickening agents such as cellulose derivatives, for example 1 - 100 mg/ml if present, sweeteners such as aspartame or equivalent sugars, eg 0.5-5 mg/ml, and flavouring agents such as fruit flavourings and syrup flavourings, eg 10-20 mg/ml etc.
- suspending agents such as Xantham gum, for example 0.25-5 mg/ml, suitably 0.5 - 2.5 mg/ml
- thickening agents such as cellulose derivatives, for example 1 - 100 mg/ml if present
- sweeteners such as aspartame or equivalent sugars, eg 0.5-5 mg/ml
- flavouring agents such as fruit flavourings and syrup flavourings, eg 10-20 mg
- Silicas such as "Aerosil” may be present as thickening agents and/or as a powder flow aid, and other silicas such as "Syloid” may be present as an internal dessicant and bulking agent. Typically silicas may be present at eg 1-100 mg/ml. Dry powder, granule or tablet formulations for reconstitution may contain corresponding weights of these and/or other conventional excipients.
- Aqueous suspension and solution formulations of this invention may be provided in entirely conventional bottles etc, and dry powder or granule formulations for reconstitution may be provided in conventional jars, sachets etc which are advisedly airtight.
- the formulations of the invention appear to offer a number of advantages over known formulations which contain a ⁇ -lactam antibiotic in combination with clavulanic acid or clavulanate equivalent. These include improvement of stability in solution for example by 2-4% of the initial concentration on storage for 7 days at 5°C. The stability in solution is more robust in terms of pH differences in the water used to make up the suspension or solution and the quality of raw materials such as amoxycillin trihydrate. The presence of succinate ion appears to inhibit the colour change from white to pale cream that sometimes follows reconstitution, and there appears to be some enhancement of the flavour of reconstituted suspensions and solutions.
- the invention also provides a process for the preparation of such a pharmaceutical formulation, comprising admixing the ⁇ -lactam antibiotic, the clavulanic acid or salt thereof, the dicarboxylic acid and the salt thereof, and optionally any excipients, and optionally making the product up with water or an aqueous medium to form a suspension or solution formulation.
- the invention also provides a process for the use of a pharmaceutical formulation as described above in the manufacture of a medicament for the treatment of bacterial infections.
- the invention also provides a pharmaceutical formulation as described above for use in the treatment of bacterial infections.
- the invention also provides a method of treatment of bacterial infections in humans or animals which comprises the administration of a therapeutically effective amount of a pharmaceutical formulation as described above.
- a unit dose of 5ml of this suspension contains 156 mg of amoxycillin clavulanic acid combination.
- This suspension contains 112.5 mg per ml of amoxycillin clavulanic acid combination.
- a unit dose of 5 ml of this suspension contains 312 mg of amoxycillin/clavulanic acid combination.
- a unit dose of 5ml of this suspension contains 187 mg of amoxycillin clavulanic acid combination.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulation pharmaceutique comprenant une ou plusieurs bêta-lactamines, de l'acide clavulanique ou un sel de celui-ci, soluble dans l'eau, un acide dicarboxylique pharmaceutiquement acceptable, et un sel de l'acide dicarboxylique, dans lequel les deux atomes d'hydrogène acides sont remplacés par un cation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9114950 | 1991-07-11 | ||
GB919114950A GB9114950D0 (en) | 1991-07-11 | 1991-07-11 | Pharmaceutical formulation |
PCT/GB1992/001207 WO1993000898A1 (fr) | 1991-07-11 | 1992-07-03 | Formulation pharmaceutique comprenant une beta-lactamine et de l'acide clavulanique ou un sel de celui-ci soluble dans l'eau |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0593573A1 true EP0593573A1 (fr) | 1994-04-27 |
Family
ID=10698173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92914294A Withdrawn EP0593573A1 (fr) | 1991-07-11 | 1992-07-03 | Formulation pharmaceutique comprenant une beta-lactamine et de l'acide clavulanique ou un sel de celui-ci soluble dans l'eau |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0593573A1 (fr) |
JP (1) | JPH06508844A (fr) |
AU (1) | AU2230692A (fr) |
GB (1) | GB9114950D0 (fr) |
WO (1) | WO1993000898A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011142731A2 (fr) | 2010-05-14 | 2011-11-17 | Mahmut Bilgic | Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération |
WO2011142730A1 (fr) | 2010-05-14 | 2011-11-17 | Mahmut Bilgic | Composition pharmaceutique comprenant la céfixime et un composé dérivé de l'acide clavulanique |
WO2011152808A1 (fr) | 2010-06-03 | 2011-12-08 | Mahmut Bilgic | Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT862431E (pt) | 1995-09-07 | 2002-04-29 | Smithkline Beecham Plc | Utilizacao de uma formulacao farmaceutica pediatrica que compreende amoxicilina e clavulanato |
US5759579A (en) * | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
DE19706978A1 (de) * | 1997-02-21 | 1998-08-27 | Ulrich Dr Posanski | Kombinationspräparat für oral applizierbare Antibiotika |
US20010016577A1 (en) * | 1998-08-24 | 2001-08-23 | Douglas Joseph Dobrozsi | Oral mucoadhesive compositions containing gastrointestinal actives |
US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
EP1330236A2 (fr) | 2000-10-12 | 2003-07-30 | Beecham Pharmaceuticals (Pte) Limited | Nouvelle formulation |
EP1941873A4 (fr) | 2005-09-22 | 2012-09-26 | Meiji Seika Kaisha | Inhibiteur de la métallo-pénicillinase |
TR201000688A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3266580D1 (en) * | 1981-12-02 | 1985-10-31 | Beecham Group Plc | Pharmaceutical formulation comprising beta-lactam antibiotics |
GB9007945D0 (en) * | 1990-04-07 | 1990-06-06 | Beecham Group Plc | Pharmaceutical formulation |
-
1991
- 1991-07-11 GB GB919114950A patent/GB9114950D0/en active Pending
-
1992
- 1992-07-03 WO PCT/GB1992/001207 patent/WO1993000898A1/fr not_active Application Discontinuation
- 1992-07-03 EP EP92914294A patent/EP0593573A1/fr not_active Withdrawn
- 1992-07-03 JP JP5502080A patent/JPH06508844A/ja active Pending
- 1992-07-03 AU AU22306/92A patent/AU2230692A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9300898A1 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011142731A2 (fr) | 2010-05-14 | 2011-11-17 | Mahmut Bilgic | Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération |
WO2011142730A1 (fr) | 2010-05-14 | 2011-11-17 | Mahmut Bilgic | Composition pharmaceutique comprenant la céfixime et un composé dérivé de l'acide clavulanique |
WO2011152808A1 (fr) | 2010-06-03 | 2011-12-08 | Mahmut Bilgic | Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique |
Also Published As
Publication number | Publication date |
---|---|
JPH06508844A (ja) | 1994-10-06 |
AU2230692A (en) | 1993-02-11 |
WO1993000898A1 (fr) | 1993-01-21 |
GB9114950D0 (en) | 1991-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU722657B2 (en) | Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia | |
US4676984A (en) | Rehydratable antacid composition | |
EP0593573A1 (fr) | Formulation pharmaceutique comprenant une beta-lactamine et de l'acide clavulanique ou un sel de celui-ci soluble dans l'eau | |
US6726908B2 (en) | Pharmaceutical formulation | |
EP0825860B1 (fr) | Utilisation d'une composition a base d'amoxycilline et d'acide clavulanique pour la preparation d'un medicamente pour le traitement des infections bacterielles pour enfants | |
AU762840B2 (en) | Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose | |
EP1142573B1 (fr) | COMPOSITIONS pharmaceutiques comprenant du faropenem sodium et un diamine acétate pour améliorer l'absorption gastrointestinale | |
US4704278A (en) | Fluidized magaldrate suspension | |
US6066629A (en) | Storage stable amoxycillin and clavulanate suspension composition | |
WO2001045667A2 (fr) | Poudres hydrosolubles destinees a des solutions orales et leur utilisation | |
US4272542A (en) | Use of di-sodium and di-potassium salts of dicarboxylic amino acids and tri- or di-sodium or potassium phosphate tartrate or citrate to improve the taste of in vivo hydrolysable esters of α-amino penicillins and cephalosporins | |
EP0178895B1 (fr) | Compositions de magaldrate fluidisées et réhydratables | |
US20020099044A1 (en) | Composition comprising amoxycillin and clavulanic acid | |
WO1997006798A2 (fr) | Preparations pharmaceutiques | |
WO2000050036A1 (fr) | Composition sous forme de suspension a stockage stable a base d'amoxycilline et de clavulanate | |
EP0008178A2 (fr) | Poudre, procédé pour sa préparation, récipient la contenant, et sirop comprenant la poudre reconstituée avec de l'eau | |
EP0008179A2 (fr) | Poudre, procédé pour sa préparation, récipient la contenant, et sirop comprenant la poudre reconstituée avec de l'eau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19931116 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 19980203 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19980814 |